Ömer BOZDOĞAN, Nuran EKERBİÇER, Ersöz GONCA

Effects of adenosine A1 receptor agonist CCPA and antagonist DPCPX on ischemia/reperfusion-induced arrhythmias in rats

Amaç: Adenozin supraventriküler taşikardili hastaların tedavisinde kullanılan etkili bir ilaçtır. Ancak, adenozinin iskemi ve reperfüzyon aritmileri üzerine adsenozin etkisi ile ilgili sadece bir kaç çalışma vardır ve bunlarında sonuçları tartışmalıdır. Bu çalışmada adenozinin iskemi-reperfüzyon aritmileri üzerine etkisinin araştırılması amaçlanmıştır.Yöntem ve gereç: Sol koroner arter bağlanarak 6 dakika iskemi ve bağ gevşetilerek 15 dakika reperfüzyon yapılmıştır. Bir A1 adenozin reseptor agonisti olan CCPA (2 Chloro - N6 – Cyclopentyl-adenosine) ve anatgonisti, DPCPX (8- Cyclopentyl-1,3-dipropylxanthine), 5 μg/kg dozunda tek ve birlikte iskemiden önce, iskeminin ikinci dakikasında ve reperfüzyonu hemen takiben intravenöz olarak verilmiştir.Bulgular: Sadece ligasyonun ikinci dakikasında verilen CCPA, 15 dakikalık reperfüzyon boyunca oluşan aritmi süresini azaltmıştır. Bu dönemde verilen adenozin antagonisti, DPCPX, adenozinin bu antiaritmik etkisini ortadan kaldırmıştır. Reperfüzyon sırasında ve ligasyondan önce verilen adenozinin reperfüzyonu takiben oluşan aritmiler üzerine bir etkisi olmamıştır.Sonuç: İskemi ve reperfüzyon sırasında veriliş zamanı, adenozinin etkisinde önemlidir. Bu çalışma adenozin ile oluşturulan antiaritminin, A1 adenozin reseptorlarının aktivasyonu ile ilgili olduğunu göstermiştir.

Sıçanlarda, adenozin agonisti, CCPA, ve antagonisti DPCPX’in iskemi / reperfüzyon ile uyarılan aritmiler üzerine etkisi

Aim: Adenosine has been commonly used to treat supraventricular tachycardia in clinics. However, there are only a few studies on the effects of adenosine on ischemia or reperfusion induced arrhythmia and they conflict with the results of the present study. During this study, we aimed to clarify the effect of adenosine on ischemia-reperfusion induced arrhythmia.Materials and methods: Left coronary artery was ligated for 6 min and it was released for 15 min to produce reperfusion. A1 adenosine agonist CCPA (2 Chloro - N6 – Cyclopentyl-adenosine), and A1 selective antagonist DPCPX (8 – Cyclopentyl - 1,3 -dipropylxanthine) in 5 μg/kg dose alone and in combination were given intravenously before ligation, at the second minute of the ligation and just following the reperfusion.Results: Adenosine given only at the second minute of the ligation is found to decrease the total duration of arrhythmia observed in the reperfusion stage. DPCPX given in this period is found to block the antiarrhythmic effect of adenosine. Adenosine given after reperfusion and before ligation was not effective in decreasing reperfusion induced arrhythmia.Conclusion: The time dependent effect of the administration during ischemia and reperfusion was important for the effect of adenosine. The present study showed that antiarrhythmia produced by adenosine is related to the activation of A1 adenosine receptor.

PDF

___

1. Overholt ED, Rheuban KS, Gutgesell HP, Lerman BB, Dimarco JP. Usefulness of adenosine for arrhythmias in infants and children. Am J Cardiol 1988; 61: 336-340.
2. Wilbur SL., Marchlinski FE. Adenosine as an antiarrhythmic agent. Am J Cardiol 1997; 79: 30-37.
3. Noji T, Karasawa A, Kusaka H. Adenosine uptake inhibitors. Eur J Pharmacol 2004; 495: 1-16.
4. Tan HL, Spekhorst HHM, Peters RJG, Wilde AAM. Adenosine induced ventricular arrhythmias in the emergency room. PACE 2001; 24: 450-455.
5. Obata T. Adenosine production and its interaction with protection of ischemic and reperfusion injury of the myocardium. Life Sci 2002; 71: 2083-2103.
6. Mubagwa K, Flameng W. Adenosine, adenosine receptors and myocardial protection: An updated overview. Cardiovasc Res 2001; 52: 25-39.
7. De Jonge RD, Out M, Maas WJ, De Jong JW. Preconditioning of rat hearts by adenosine A1 or A3 receptor activation. Eur J Pharmacol 2002; 441: 165-172.
8. Miura T, Ishimoto R, Sakamoto J, Tsuchida A, Suzuki K, Ogawa T et al. Suppression of reperfusion arrhythmia by ischemic preconditioning in the rat: Is it mediated by the adenosine receptor, prostoglandin, or bradykinin receptor? Basic Res Cardiol 1995; 90: 240-246.
9. Vegh A, Papp JG, Parratt JR. Pronounced antiarrhythmic effects of preconditioning in anaesthetized dogs: is adenosine involved? J Mol Cell Cardiol 1995; 27: 349-356.
10. Ganote CE, Armstrong SC. Adenosine and preconditioning in the rat heart. Cardiovasc Res 2000; 45: 134-140.
11. Tissier R, Souktani R, Parent de Curzon O, Lellouche N, Henry P, Giudicelli JF et al. Pharmacological delayed preconditioning against ischemia-induced ventricular arrhythmias: Effect of an adenosine A1-receptor agonist. Br J Pharmacol 2001; 134: 1532-1538.
12. Wainwright CL, Parratt JR. Effects of R-PIA, a selective A1 adenosine agonist, on haemodynamics and ischaemic arrhythmias in pigs. Cardiovasc Res 1993; 27: 84-89.
13. Wainwright CL, Parratt JR. An antiarrhythmic effect of adenosine during myocardial ischaemia and reperfusion. Eur J Pharmacol 1988; 145: 183-194.
14. Pelleg A, Kutalek SP. Adenosine in the mammalian heart: nothing to get excited about. TIPS 1997; 18: 236-238.
15. Canyon SJ, Dobson GP. Pretreatment with an adenosine A1 receptor agonist and lidocaine: A possible alternative to myocardial ischemic preconditioning. J Thorac Cardiovasc Surg 2005; 130: 371-377.
16. Walker MJA, Curtis MJ, Hearse DJ, Campbell RWF, Janse MJ, Yellon DM et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc Res 1988; 22: 447-455.
17. Shen FM, Zhu GM, Miao CY, Guan YF, Su DF. ATP-sensitive potassium channels are involved in adenosine-induced reduction of blood pressure variability in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2004; 44: 87-92.
18. Belloni FL, Wang J, Hintze TH. Adenosine causes bradycardia in pacing-induced cardiac failure. Circulation 1992; 85: 1118-24.
19. Baxter GF. Role of adenosine in delayed preconditioning of myocardium. Cardiovasc Res 2002; 55: 483-494.
20. Grover GJ. Protective effects of ATP-sensitive potassium- channel openers in experimental myocardial ischemia. J Cardiovasc Pharmacol 1994; 24: S18-S27.
21. Cohen NM, Wise RM, Wechsler AS, Damiano RJ Jr. Elective cardiac arrest with a hyperpolarizing adenosine triphosphatesensitive potassium channel opener. A novel form of myocardial protection? J Thorac Cardiovasc Surg 1993; 106: 317-28.
22. Baczko I, Lepran I, Papp J Gy. KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthtized rats. Eur J Pharmacol 1997; 324: 77-83.
23. Black SC, Lucchesi BR. Potassium channel openers are likely to be proarrhythmic in the diseased human heart. Cardiovasc Res 1994; 28: 923.
24. Kaiser J, Englert HC, Kurjat M, Linz W. Profibrillatory effect of pinacidil and its antagonism by low concentrations of glibenclamide in isolated guinea pig hearts. Naunyn- Schmiedeberg’s Arch Pharmacol 1994; 349: R46.
25. Bozdoğan Ö, Lepran I, Papp JGy. The effect of ATP-dependent potassium channel blocker, Glimeprid, on the arrhythmias observed following ischemia and reperfusion in anesthesized Rats. Tr J of Vet Anim Sci 1998; 22: 247-254.
26. Bozdogan Ö, Gonca E, Nebigil M, Tiryaki SE. Effect of Thimerosal on arrhythmia induced by coronary ligation: the involvement of ATP-dependent potassium channels. Int Heart J 2005; 46: 711-722.
27. Lee YM, Chern JW, Yen MH. Antiarrhythmic effects of BN-063, a newly synthesized adenosine A1 agonist, on myocardial ischemia in rats. Br J Pharmacol 1994; 112: 1031-1036.